Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Berberis Aquifolium Root Bark is a non-standardized plant allergenic extract and adrenergic agonist used in clinical immunology and integrative medicine. It functions primarily through alpha- and beta-adrenergic receptor pathways to modulate physiological responses.
Name
Berberis Aquifolium Root Bark
Raw Name
BERBERIS AQUIFOLIUM ROOT BARK
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
23
Variant Count
27
Last Verified
February 17, 2026
About Berberis Aquifolium Root Bark
Berberis Aquifolium Root Bark is a non-standardized plant allergenic extract and adrenergic agonist used in clinical immunology and integrative medicine. It functions primarily through alpha- and beta-adrenergic receptor pathways to modulate physiological responses.
Detailed information about Berberis Aquifolium Root Bark
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Berberis Aquifolium Root Bark.
Berberis Aquifolium Root Bark, derived from the plant commonly known as Oregon Grape, is a complex botanical substance utilized in clinical pharmacology primarily as a Non-Standardized Plant Allergenic Extract [EPC]. Within the regulatory framework of the United States Food and Drug Administration (FDA), this substance is categorized under several pharmacological classes, including Adrenergic alpha-Agonists [MoA] and Adrenergic beta-Agonists [MoA]. This dual classification reflects its multifaceted role: it serves both as an antigen for diagnostic and therapeutic immunological purposes and as a pharmacologically active agent that influences the autonomic nervous system.
Historically, Berberis Aquifolium has been recognized in pharmacopeias for its rich alkaloid content, particularly berberine, berbamine, and oxyacanthine. In contemporary clinical settings, it is often employed in the formulation of allergenic extracts used for skin testing or immunotherapy, as well as in specific homeopathic preparations for dermatological and gastrointestinal conditions. The FDA approval history for Berberis Aquifolium extracts often falls under the grandfathered provisions for allergenic products or is regulated as a homeopathic active ingredient under the HPUS (Homeopathic Pharmacopoeia of the United States) standards. It is essential to distinguish between the raw botanical material and the clinically prepared extracts used in medical practice. Your healthcare provider may utilize this extract to identify specific sensitivities or to manage chronic inflammatory conditions through regulated sympathetic nervous system modulation.
The mechanism of action for Berberis Aquifolium Root Bark is significantly driven by its isoquinoline alkaloids. At the molecular level, these compounds interact with the adrenergic receptor system. As an Adrenergic alpha-Agonist, the active constituents bind to alpha-1 and alpha-2 receptors, potentially inducing vasoconstriction and modulating smooth muscle tone. Simultaneously, its role as an Adrenergic beta-Agonist involves the stimulation of beta-receptors, which can influence heart rate, bronchodilation, and metabolic processes such as lipolysis.
Beyond its adrenergic activity, the extract serves as a Non-Standardized Plant Allergenic Extract. In this capacity, it introduces specific plant proteins to the immune system. When used in immunotherapy, the goal is to induce desensitization by shifting the immune response from a Th2-dominated (allergic) profile to a Th1-dominated profile, thereby increasing the production of IgG4 blocking antibodies and reducing IgE-mediated mast cell degranulation. This dual-action profile—modulating both the nervous and immune systems—makes it a unique tool in the management of complex hypersensitivity and inflammatory disorders.
Understanding the pharmacokinetics of Berberis Aquifolium Root Bark is challenging due to its nature as a non-standardized extract containing multiple bioactive compounds. However, data on its primary alkaloid, berberine, provides a clinical proxy for its behavior in the human body.
Berberis Aquifolium Root Bark is utilized for several clinical indications, though its use is often specialized:
Berberis Aquifolium Root Bark is available in several pharmaceutical and clinical preparations:
> Important: Only your healthcare provider can determine if Berberis Aquifolium Root Bark is right for your specific condition. The choice of form and dosage depends heavily on the clinical indication being treated.
The dosage of Berberis Aquifolium Root Bark varies significantly based on the indication and the specific preparation used. For oral administration of standardized extracts (containing 5-10% alkaloids), the typical adult dosage ranges from 250 mg to 500 mg, taken two to three times daily. When used as a tincture (1:5 dilution), the common dose is 2-4 mL three times a day.
In the context of allergenic immunotherapy, dosing is highly individualized. It begins with a 'build-up phase' using extremely dilute concentrations (e.g., 0.01 mL of a 1:100,000 w/v dilution) and gradually increases over several months to a maintenance dose (e.g., 0.5 mL of a 1:100 w/v dilution). Because this is a non-standardized extract, the potency may vary between manufacturers, and clinicians must follow the specific labeling of the product being used.
Berberis Aquifolium Root Bark is not generally recommended for use in infants or very young children due to the risk of kernicterus (a type of brain damage) associated with berberine in neonates. For older children (ages 12 and up), healthcare providers may prescribe reduced dosages, often calculated based on body weight (e.g., 5-10 mg/kg/day of standardized extract). However, pediatric use must be strictly supervised by a specialist, particularly when used as an allergenic extract for immunotherapy.
There are limited clinical trials regarding the use of Berberis Aquifolium in patients with kidney disease. However, since a portion of the alkaloids is excreted renally, a dose reduction of 25-50% may be considered for patients with a Creatinine Clearance (CrCl) below 30 mL/min to prevent systemic accumulation and toxicity.
As the liver is the primary site of metabolism for this extract's alkaloids, patients with hepatic impairment (Child-Pugh Class B or C) should use this medication with extreme caution. Dose adjustments are necessary, and frequent monitoring of liver function tests (LFTs) is recommended during the course of treatment.
Geriatric patients may be more sensitive to the adrenergic effects of the extract, such as increased heart rate or blood pressure. It is generally advised to 'start low and go slow,' beginning at the lowest end of the adult dosing spectrum and monitoring for cardiovascular side effects.
For oral forms, Berberis Aquifolium Root Bark should ideally be taken with food to minimize gastrointestinal irritation. Capsules should be swallowed whole; do not crush or chew them unless specifically instructed by your pharmacist, as this may alter the absorption rate. For topical applications, apply a thin layer to the affected area and wash hands thoroughly after use. If using for immunotherapy, the injection must be administered in a clinical setting equipped to handle anaphylaxis, and the patient must remain under observation for at least 30 minutes following the dose.
Storage conditions are critical: keep the extract in a cool, dry place away from direct sunlight. Injectable extracts must typically be refrigerated between 2°C and 8°C (36°F to 46°F).
If you miss a dose of the oral extract, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. For missed immunotherapy injections, contact your allergist immediately, as a dosage reduction may be necessary if too much time has elapsed between treatments.
Signs of an overdose of Berberis Aquifolium Root Bark include severe nausea, vomiting, diarrhea, labored breathing (dyspnea), decreased heart rate (bradycardia), and in extreme cases, seizures or cardiovascular collapse. If an overdose is suspected, contact a poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining airway patency and cardiovascular stability.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Non-standardized extracts require careful professional oversight to ensure safety and efficacy.
Patients taking Berberis Aquifolium Root Bark frequently report gastrointestinal disturbances. These include mild nausea, stomach cramping, and a change in bowel habits (either constipation or diarrhea). These symptoms often occur within the first week of treatment as the body adjusts to the alkaloids. When used topically, common side effects include a mild burning or stinging sensation at the site of application and temporary skin redness. These effects are generally transient and do not require discontinuation of the medication.
Some patients may experience systemic effects related to the extract's adrenergic activity. This can manifest as a mild increase in heart rate (tachycardia), a feeling of nervousness or jitteriness, and occasional insomnia if the dose is taken late in the evening. Some individuals report a metallic taste in the mouth or a slight yellowing of the skin (not to be confused with jaundice) due to the vibrant yellow color of the berberine alkaloid.
Rare but documented side effects include photosensitivity (increased sensitivity to sunlight), which can lead to rapid sunburn. There have been isolated reports of leukopenia (reduced white blood cell count) with prolonged, high-dose oral use. Some patients may develop a localized rash or hives (urticaria) that is not part of the intended immunological response.
> Warning: Stop taking Berberis Aquifolium Root Bark and call your doctor immediately if you experience any of these.
Prolonged use of Berberis Aquifolium Root Bark (exceeding 8 weeks of continuous oral use) may lead to alterations in the gut microbiome due to the antimicrobial properties of berberine. There is also a theoretical risk of vitamin B deficiency, as the alkaloids may interfere with certain absorption pathways in the ileum. Long-term topical use on large surface areas may lead to systemic absorption, potentially increasing the risk of the adrenergic side effects mentioned above.
No FDA black box warnings for Berberis Aquifolium Root Bark have been issued as of 2026. However, clinical guidelines emphasize that allergenic extracts must only be administered by healthcare professionals prepared to treat life-threatening anaphylaxis. The lack of a black box warning does not imply the drug is without risk; rather, it indicates that the risks are currently managed through standard clinical precautions and labeling.
Report any unusual symptoms to your healthcare provider. Monitoring of blood counts and liver enzymes may be required for patients on long-term therapy.
Berberis Aquifolium Root Bark contains potent alkaloids that act on the autonomic nervous system and the immune system. It is not a simple herbal supplement but a pharmacologically active extract. Patients with a history of cardiovascular disease, liver dysfunction, or severe allergies must be evaluated thoroughly before use. It is vital to inform your healthcare provider of all other medications you are taking, as the extract's influence on the cytochrome P450 enzyme system can significantly alter the levels of other drugs in your bloodstream.
No FDA black box warnings for Berberis Aquifolium Root Bark. While the FDA has not mandated a black box warning, the agency requires that all non-standardized allergenic extracts carry a prominent warning regarding the risk of severe systemic reactions, including anaphylaxis, which can be fatal.
Healthcare providers typically recommend the following monitoring schedule for patients on systemic Berberis Aquifolium therapy:
Berberis Aquifolium Root Bark may cause dizziness or jitteriness in some patients due to its adrenergic effects. Do not drive or operate heavy machinery until you know how this medication affects you. If you experience palpitations or lightheadedness, avoid these activities and consult your doctor.
Alcohol should be avoided or strictly limited while taking this extract. Alcohol can exacerbate the gastrointestinal side effects and may increase the risk of liver strain when combined with the alkaloids in Berberis Aquifolium. Furthermore, alcohol can mask the early signs of an allergic reaction or adrenergic overstimulation.
Do not stop taking Berberis Aquifolium Root Bark suddenly if you have been using it for a prolonged period. While it does not have a traditional withdrawal syndrome, sudden discontinuation of an adrenergic agonist can lead to 'rebound' effects or a flare-up of the condition being treated. Your doctor will provide a tapering schedule to safely reduce your dose.
> Important: Discuss all your medical conditions with your healthcare provider before starting Berberis Aquifolium Root Bark.
Berberis Aquifolium Root Bark may interfere with certain laboratory tests:
For each major interaction, the management strategy involves either avoiding the combination or performing rigorous clinical monitoring to ensure the patient's safety and the therapeutic efficacy of all involved medications.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Berberis Aquifolium Root Bark must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients who are allergic to other members of the Berberidaceae family (such as Barberry or Goldthread) may exhibit cross-sensitivity to Berberis Aquifolium Root Bark. Additionally, those with sensitivities to other plant-based adrenergic agents should be monitored closely for similar allergic or physiological responses.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Berberis Aquifolium Root Bark to ensure that no contraindications are present.
Berberis Aquifolium Root Bark is strictly contraindicated during pregnancy. It is classified as a high-risk substance due to the presence of berberine. Clinical data and animal studies suggest that berberine can cause uterine contractions, which may increase the risk of preterm labor or spontaneous abortion. Furthermore, berberine has a high affinity for albumin, displacing bilirubin. In a developing fetus, this can lead to elevated levels of free bilirubin, which crosses the undeveloped blood-brain barrier, potentially causing permanent neurological damage (kernicterus). There is no safe dosage for pregnant women.
Use during breastfeeding is not recommended. The alkaloids in Berberis Aquifolium Root Bark pass into breast milk. Nursing infants, particularly those under six months old, have immature liver enzymes and are at significant risk for the bilirubin-displacement effects mentioned above. If a nursing mother must use this extract, breastfeeding should be discontinued, and an alternative infant feeding method should be established.
The safety and efficacy of Berberis Aquifolium Root Bark in children under the age of 12 have not been established through rigorous clinical trials. In older children, it is primarily used under the guidance of an allergist for immunotherapy. Growth effects have not been formally studied, but given its adrenergic MoA, long-term use could theoretically impact metabolic rate and growth patterns. It is NOT approved for use in neonates or infants due to the severe risk of brain damage.
Elderly patients are at an increased risk for adverse effects from Berberis Aquifolium Root Bark. Age-related declines in renal and hepatic function mean that the drug remains in the system longer, increasing the risk of toxicity. Furthermore, the adrenergic stimulation (alpha and beta) can be particularly hard on the aging cardiovascular system, increasing the risk of falls due to dizziness or palpitations. Polypharmacy is also a major concern, as the elderly are often on multiple medications that interact with the CYP3A4 pathway.
In patients with impaired kidney function, the clearance of Berberis metabolites is reduced. For patients with a GFR between 30 and 60 mL/min, a cautious approach with frequent monitoring is required. For those with a GFR below 30 mL/min, the drug is generally avoided unless the clinical need outweighs the risks. It is not known if the active components are cleared by hemodialysis.
Patients with hepatic impairment are at the highest risk for systemic toxicity. The liver's inability to process the isoquinoline alkaloids leads to rapid increases in serum concentrations. Use in patients with Child-Pugh Class B or C is generally avoided. In milder cases (Class A), doses should be reduced by at least 50%, and liver enzymes should be checked monthly.
> Important: Special populations require individualized medical assessment to prevent severe adverse outcomes.
Berberis Aquifolium Root Bark exerts its effects through a complex interplay of alkaloid-receptor interactions. The primary mechanism involves the stimulation of both alpha- and beta-adrenergic receptors. As an alpha-adrenergic agonist, it mimics the effects of norepinephrine, leading to the activation of G-protein coupled receptors that increase intracellular calcium levels, resulting in smooth muscle contraction and peripheral vasoconstriction. As a beta-adrenergic agonist, it stimulates adenylate cyclase, increasing cAMP levels, which leads to bronchodilation and positive inotropic effects on the heart.
Additionally, the extract contains berberine, which has been shown to inhibit the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to increased clearance of LDL cholesterol from the blood. It also activates AMP-activated protein kinase (AMPK), a master regulator of metabolism, which explains its effects on glucose and lipid levels.
The pharmacodynamic response to Berberis Aquifolium is dose-dependent. Low doses primarily affect the gastrointestinal tract and immune signaling, while higher doses produce systemic adrenergic effects. The onset of action for oral forms is typically 1-2 hours, with a duration of effect lasting approximately 4-8 hours. Tolerance to the adrenergic effects may develop with chronic use, requiring dose adjustments.
| Parameter | Value |
|---|---|
| Bioavailability | < 5% (Oral) |
| Protein Binding | 70% - 85% |
| Half-life | 3 - 6 hours |
| Tmax | 1.5 - 2.5 hours |
| Metabolism | Hepatic (CYP3A4, CYP2D6) |
| Excretion | Renal (20%), Fecal (80%) |
The extract is a complex mixture, but its primary markers are isoquinoline alkaloids. The molecular formula for the dominant alkaloid, Berberine, is C20H18NO4+. It has a molecular weight of 336.36 g/mol. The extract is soluble in ethanol and moderately soluble in water. Structurally, it is characterized by a quaternary ammonium salt structure which contributes to its vibrant yellow color and its ability to interact with various biological membranes.
Berberis Aquifolium Root Bark is classified as a Non-Standardized Plant Allergenic Extract [EPC]. It also falls under the functional classes of Adrenergic alpha-Agonists and Adrenergic beta-Agonists. Related medications include other berberine-containing plants like Berberis vulgaris (Barberry) and Hydrastis canadensis (Goldenseal), as well as synthetic adrenergic agents like phenylephrine or isoproterenol, though its botanical origin provides a much broader spectrum of activity.
Medications containing this ingredient
Common questions about Berberis Aquifolium Root Bark
Berberis Aquifolium Root Bark is primarily used as a clinical allergenic extract for diagnosing and treating plant-based allergies through immunotherapy. In integrative medicine, it is also utilized for its anti-inflammatory properties to manage skin conditions like psoriasis and eczema. Because it acts as an adrenergic agonist, it can help modulate the sympathetic nervous system's response in specific inflammatory profiles. Additionally, it has a long history of use in supporting gastrointestinal health and metabolic function. Always consult a healthcare provider to see if this extract is appropriate for your specific medical needs.
The most frequently reported side effects include gastrointestinal issues such as nausea, stomach cramps, and diarrhea, which typically occur when the extract is taken orally. For those using topical preparations, local skin irritation, redness, or a mild burning sensation are common. Some patients may also experience systemic adrenergic effects, including a slightly elevated heart rate or a feeling of nervousness. Most of these symptoms are mild and tend to resolve as the body becomes accustomed to the medication. If side effects persist or worsen, you should contact your doctor immediately.
It is generally advised to avoid alcohol while using Berberis Aquifolium Root Bark. Alcohol can worsen the gastrointestinal side effects of the extract and may increase the risk of liver toxicity when combined with the plant's alkaloids. Furthermore, alcohol can interfere with the extract's adrenergic effects, potentially leading to unpredictable changes in blood pressure or heart rate. Alcohol consumption may also make it more difficult for you to recognize the early signs of a serious allergic reaction. Discuss your alcohol intake with your healthcare provider before starting this treatment.
No, Berberis Aquifolium Root Bark is considered unsafe during pregnancy and is strictly contraindicated. The active alkaloid, berberine, can cause uterine contractions that may lead to miscarriage or premature labor. More critically, it can displace bilirubin from albumin in the fetus, leading to a dangerous condition called kernicterus, which causes permanent brain damage. Women who are pregnant or planning to become pregnant should avoid all forms of this extract. If you discover you are pregnant while taking this medication, stop use immediately and contact your obstetrician.
The time it takes for Berberis Aquifolium Root Bark to show results depends on the condition being treated. For gastrointestinal symptoms, some patients may feel relief within 24 to 48 hours. When used for skin conditions like psoriasis, it may take 4 to 8 weeks of consistent use before a significant reduction in redness and scaling is visible. In the case of allergenic immunotherapy, the process is much slower, often requiring several months of 'build-up' injections before the immune system begins to show desensitization. Consistency and patience are key to seeing therapeutic benefits.
You should not stop taking Berberis Aquifolium Root Bark suddenly without consulting your healthcare provider, especially if you have been using it for several weeks. Because the extract interacts with adrenergic receptors, stopping abruptly could potentially cause a 'rebound' effect, where your symptoms return more severely or you experience transient cardiovascular changes. For those undergoing immunotherapy, stopping suddenly can disrupt the desensitization process and increase the risk of an allergic reaction when treatment is resumed. Your doctor will typically recommend a gradual reduction in dose to ensure your body adjusts safely.
If you miss a dose of an oral preparation, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, simply skip the missed dose and continue with your regular routine; never take two doses at once to make up for a missed one. If you miss an appointment for an immunotherapy injection, call your allergist's office immediately. Missing an injection may require your doctor to adjust your next dose to a lower concentration to prevent an adverse reaction. Keeping a consistent schedule is vital for the success of the treatment.
There is no significant clinical evidence suggesting that Berberis Aquifolium Root Bark causes weight gain. In fact, some studies on its primary alkaloid, berberine, suggest it may actually support weight management by activating AMPK, which helps regulate metabolism and fat burning. However, because the extract can affect the adrenergic system, some individuals might experience changes in appetite or metabolic rate. If you notice unusual changes in your weight while taking this medication, it is important to discuss them with your healthcare provider. Individual responses to botanical extracts can vary widely.
Berberis Aquifolium Root Bark has a high potential for drug interactions because it affects liver enzymes like CYP3A4. It can significantly increase the levels of medications like cyclosporine, leading to toxicity, and may interfere with blood thinners, diabetes drugs, and blood pressure medications. Because of these risks, it is essential to provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are currently taking. Your healthcare provider will monitor you closely for any signs that your other medications are not working correctly or are causing increased side effects.
Berberis Aquifolium Root Bark is a botanical extract and is not 'generic' in the same way synthetic drugs like ibuprofen are. However, it is available from many different manufacturers under various brand names and as unbranded bulk extracts. Because it is a 'non-standardized' extract, the concentration of active alkaloids can vary significantly between different products. It is important to use a high-quality product from a reputable manufacturer and to stay with the same brand throughout your treatment to ensure consistent dosing. Your pharmacist or doctor can help you select a reliable version of the extract.